PI3K pathway-directed therapeutic strategies in cancer

Roshan Agarwal, Mark Carey, Bryan Hennessy, Gordon B. Mills

    Research output: Contribution to journalReview article

    40 Scopus citations


    PI3K pathway signaling is the focus of intensive oncology drug-development programs at several academic institutions and pharmaceutical companies. With several drugs that target different parts of the pathway in early clinical trials, this review presents evidence demonstrating that the PI3K pathway represents a suitable target for cancer drug development, discusses therapeuticstrategies for targeting the pathway, and highlights the status of drugs currently in development.

    Original languageEnglish (US)
    Pages (from-to)615-628
    Number of pages14
    JournalCurrent Opinion in Investigational Drugs
    Issue number6
    StatePublished - Jun 1 2010



    • Akt
    • Cancer
    • Drug development
    • Growth factor signaling
    • PI3K
    • Phase I clinical trial
    • Targeted therapy

    ASJC Scopus subject areas

    • Pharmacology
    • Drug Discovery

    Cite this